A well-known complication of gout is an increased risk for nephrolithiasis (NL). The incidence rate of NL in the general population varies in different studies between 85 and 170/100 000 person-years, with a peak incidence in the ages 40-49 years. Several medications used in gout patients could affect the risk for NL, including allopurinol, losartan, thiazide-and loop-diuretics. Effect of these medications on risk of NL in gout patients, and the general population, has only scarcely been studied. Objectives: In this cohortstudy we investigated: 1) overall incidence of NL in gout and general population (GP) controls 2) risk for first time NL in gout patients vs general population (GP) controls, and 3) predictors for first time NL in both groups separately. Methods: Gout patients were identified from the regional health care database in western Sweden (VEGA), containing ICD10-codes for all regional Healthcare visits from 2000. Matched (birthyear, sex, county) GP controls were selected from the population register. National registers and VEGA were used to retrieve information on comorbidities, socioeconomic factors and current medications at start of follow-up. The study population had to be above 19 years of age, without NL prior to start of follow-up, and living in the Western Swedish Health Care Region (WSHCR). Follow-up began 2006-01-01, or at the first gout-diagnosis if this occurred later, and ended at death, emigration or 2012-12-31, whichever occurred first. Incidence rates (IR) per 1000 person-years and hazardratios (HR) were calculated. Possible predictors for NL were based on risk factors presented in the literature. Results: 29,968 gout patients and 138,678 matched GP controls were included. In gout patients there were 678 NL-events (IR: 6.2 per 1000 pyrs at risk (95% CI: 5.7-6.6)) and in GP controls 2125 (IR 3.9 per 1000 pyrs at risk (95% CI 3.7-4.0)). Risk for NL was increased in gout (HR=1.49, 95% CI: 1.35-1.64), and was higher in men compared to women (P<0.0001) in all age groups for gout cases and controls. All comorbidities and medications were more frequent in cases compared to controls (p<0.0001) at start of follow-up. Risk-factors for NL such as kidney disease (KD), obesity, diabetes were 2-4 times more common in gout patients compared to GP controls. Predictor point estimates for NL were similar in gout cases and GP controls (Figure 1) , except for losartan which increased the
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A well-known complication of gout is an increased risk for nephrolithiasis (NL). The incidence rate of NL in the general population varies in different studies between 85 and 170/100 000 person-years, with a peak incidence in the ages 40-49 years. Several medications used in gout patients could affect the risk for NL, including allopurinol, losartan, thiazide-and loop-diuretics. Effect of these medications on risk of NL in gout patients, and the general population, has only scarcely been studied. Objectives: In this cohortstudy we investigated: 1) overall incidence of NL in gout and general population (GP) controls 2) risk for first time NL in gout patients vs general population (GP) controls, and 3) predictors for first time NL in both groups separately. Methods: Gout patients were identified from the regional health care database in western Sweden (VEGA), containing ICD10-codes for all regional Healthcare visits from 2000. Matched (birthyear, sex, county) GP controls were selected from the population register. National registers and VEGA were used to retrieve information on comorbidities, socioeconomic factors and current medications at start of follow-up. The study population had to be above 19 years of age, without NL prior to start of follow-up, and living in the Western Swedish Health Care Region (WSHCR). Follow-up began 2006-01-01, or at the first gout-diagnosis if this occurred later, and ended at death, emigration or 2012-12-31, whichever occurred first. Incidence rates (IR) per 1000 person-years and hazardratios (HR) were calculated. Possible predictors for NL were based on risk factors presented in the literature. Results: 29,968 gout patients and 138,678 matched GP controls were included. In gout patients there were 678 NL-events (IR: 6.2 per 1000 pyrs at risk (95% CI: 5.7-6.6)) and in GP controls 2125 (IR 3.9 per 1000 pyrs at risk (95% CI 3.7-4.0)). Risk for NL was increased in gout (HR=1.49, 95% CI: 1.35-1.64), and was higher in men compared to women (P<0.0001) in all age groups for gout cases and controls. All comorbidities and medications were more frequent in cases compared to controls (p<0.0001) at start of follow-up. Risk-factors for NL such as kidney disease (KD), obesity, diabetes were 2-4 times more common in gout patients compared to GP controls. Predictor point estimates for NL were similar in gout cases and GP controls (Figure 1) , except for losartan which increased the risk of NL in GP controls (HR=1,47, 95% CI: 1.01-2.13) but not in gout patients. Loop-diuretics appeared to decrease the risk for NL in both cohorts (P<0.0001), whereas other cardiovascular (CVD) drugs had no effect. Conclusions: The risk for NL was increased by 50% in gout patients, compared to controls. Overall pattern of predictors was similar in gout patients and population controls. In patients with gout, male sex, diabetes mellitus (DM), obesity predicted NL, whereas use of loop diuretics was protective. Overall, the most commonly used CVD drugs did not increase the risk for NL in patients with gout. [DiHS] ) develops during the first 2-12 weeks after initiation. SCAR risk factors include Chinese ethnicity, HLA-B*5801 positivity and chronic kidney disease. HLA-B*5801 testing to prevent SCAR has not been shown to be cost-effective in Singapore. Objectives: To retrospectively study whether a structured monitoring program (SMP) can lead to early diagnosis of allopurinol allergy and prevent development of SCAR/DiHS. Methods: SMP patients (cases) managed by rheumatologists were compared with controls managed by non-rheumatologists during the study period 1 Jan 2015 to 30 Jun 2016. Cases upon initiation of allopurinol had baseline full blood count (FBC), serum creatinine (Cr), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measured. If drug eruptions/abnormal laboratory tests developed during monitoring, allopurinol was stopped. The electronic dispensing system and computerized medical records were used for collection of patient demographics, indication for allopurinol use, initiation dose, monitoring intervals, laboratory results and clinical features of drug allergy. This was compared with the control group without an SMP. Chi square tests were used to compare differences in proportions and Mann-Whitney U test for differences in medians. P value ≤0.05 was considered statistically significant. Results: There were 61 cases and 30 controls with comparable age (p=0.81), ethnicity (>80% Chinese) (p=0.63) and estimated glomerular filtration rate, eGFR (p=0.72). There were significantly more cases with tophaceous gout (41% vs 10%, p=0.003), while more controls tumour lysis syndrome prophylaxis (30% vs 0%, p<0.001). Median (interquartile range, IQR) starting dose of 50 (50) mg was lower among cases versus controls of 100 (200) mg (p<0.001); all cases had baseline and follow-up laboratory tests compared to controls (p<0.001). Cases were followed up at a median (IQR) of 2 (1.1) weeks after initiation then 5 (2.0) weeks after the first visit, whereas controls were reviewed 8 (8.9) weeks after initiation, then 11 (4.6) weeks after the first visit. Two patients in the SMP group with normal eGFR developed maculopapular eruption (MPE), 1 elevated ALT/AST, and 1 both MPE and elevated ALT/AST within the first 14 days of initiation. One control with lymphoma and baseline eGFR 31 ml/min/1.73m 2 developed DiHS (fever, MPE, elevated ALT/AST less than twice upper limit of normal) 43 days after initiation for tumour lysis prophylaxis. This occurred while on 2-weekly monitoring of FBC, ALT, AST. There were no cases of SCAR in both groups.
